Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Endocrine 1

Conditions

Thyroid Neoplasms 1Thyroid Diseases 1Pituitary Neoplasms 1Pituitary Diseases 1Hypothyroidism 1Cancer-related Fatigue 1

Interventions

Sorafenib 3selpercatinib 2cabozantinib 2Thyroid (USP) 2Sodium 2Radiofrequency Ablation 2Metformin 2vandetanib 1tomivosertib 1temsirolimus 1repotrectinib 1pralsetinib 1pembrolizumab 1lenvatinib 1binimetinib 1apatinib 1acetaminophen, codeine drug combination 1Vitamin B 12 1Tramadol 1Thyroxine 1Thyrotropin-Releasing Hormone 1Technetium Tc 99m Sestamibi 1Surgical Procedures, Operative 1Pemetrexed 1Panobinostat 1Negative-Pressure Wound Therapy 1NAc-Sar-Gly-Val-(d-allo-Ile)-Thr-Nva-Ile-Arg-ProNEt 1Lysine Acetyltransferase 5 1Iodine-131 1Folic Acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Thyroid Diseases × Thyrotropin-Releasing Hormone × Clear all
NCT00054756 2018-08-08

Study of Thyrotropin-Releasing Hormone in Normal Volunteers and in Patients With Thyroid or Pituitary Abnormalities

National Institutes of Health Clinical Center (CC)

Phase 2 Completed
96 enrolled 6 charts
EndocrineHead & Neck

Hypothyroidism, Pituitary Diseases, Pituitary Neoplasms, Thyroid Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡